

Major shareholder announcement

November 20, 2013

In accordance with section 29 of the Danish Securities Trading Act, Novozymes hereby announces that it has been informed that Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, has decreased its holding of B shares in Novozymes to 7.45%, previously reported at 7.56% (a decrease of 0.11%).

Baillie Gifford & Co, together with its wholly owned subsidiary Baillie Gifford Overseas Limited, now holds B shares in Novozymes A/S to a total of 24,196,308 shares of a nominal value of DKK 48,392,616, equivalent to 7.45% of Novozymes A/S' share capital and 2.99% of the voting rights. The announcement is a result of Baillie Gifford Overseas Limited, a wholly owned subsidiary of Baillie Gifford & Co, decreasing its holding of B shares in Novozymes A/S to a total of 15,986,454 B shares of a nominal value of DKK 31,972,908, equivalent to 4.92% of Novozymes share capital.

Contact information

Investor Relations:

Thomas Bomhoff (DK)	+45 3077 1226	tsbm@novozymes.com
Klaus Sindahl (DK)	+45 5363 0134	ksdh@novozymes.com
Martin Riise (USA)	+1 919 649 2565	mrsn@novozymes.com

Press and media:

Rene Tronborg (DK)	+45 3077 2274	retr@novozymes.com
Frederik Bjoerndal (Europe)	+45 3077 0236	tfbh@novozymes.com
Paige Donnelly (USA)	+1 919 218 4501	pagd@novozymes.com
Meng Lian (China)	+86 136 9923 1164	mexl@novozymes.com
Henrique Pellini (Brazil)	+55 41 9288 0282	hqp@novozymes.com
Poonam Kapila (India)	+91 991 082 2339	poka@novozymes.com

Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources. Read more at www.novozymes.com.